topical RETIN-A / RENOVA and cea

[Guest guest]

Don't recall seeing this study. Kligman says tretinoin (i assume

delivered as retin-a or renova) beneficial and well tolerated for

cea. (Dr Nase says opposite).

1: Arch Dermatol 1994 Mar;130(3):319-24

A comparison of the efficacy of topical tretinoin and low-dose oral

isotretinoin

in rosacea.

Ertl GA, Levine N, Kligman AM.

University of Arizona, Tucson.

BACKGROUND AND DESIGN: Twenty-two patients with severe or

recalcitrant rosacea

were divided into three treatment groups in a randomized, double-

blind trial

that compared low-dose oral isotretinoin (10 mg/d), topically applied

tretinoin

(0.025% cream), and the combined use of both isotretinoin and

tretinoin. For the

first 16 weeks of the trial, subjects received one of these three

trial

regimens. For the final 16 weeks, isotretinoin was withheld while

tretinoin

cream or a placebo cream was continued. RESULTS: Twenty subjects

completed the

trial. Each treatment produced therapeutic benefits with regard to

the number of

papules and pustules and erythema. Treatment with oral isotretinoin

appeared to

give a more rapid onset of improvement, but there were no differences

between

the groups after 16 weeks. This level of improvement continued during

the

succeeding 16 weeks of observation whether the subjects used the

tretinoin or

the placebo cream. Adverse events were minimal and well tolerated in

all groups.

CONCLUSIONS: Low-dose oral isotretinoin and topical tretinoin cream

therapy

appear to be beneficial in the treatment of severe or recalcitrant

rosacea. No

additive benefit is noted with the combined use of these two

modalities.

Publication Types:

Clinical Trial

Randomized Controlled Trial

PMID: 8129410 [PubMed - indexed for MEDLINE]

[Guest guest]

Don't recall seeing this study. Kligman says tretinoin (i assume

delivered as retin-a or renova) beneficial and well tolerated for

cea. (Dr Nase says opposite).

1: Arch Dermatol 1994 Mar;130(3):319-24

A comparison of the efficacy of topical tretinoin and low-dose oral

isotretinoin

in rosacea.

Ertl GA, Levine N, Kligman AM.

University of Arizona, Tucson.

BACKGROUND AND DESIGN: Twenty-two patients with severe or

recalcitrant rosacea

were divided into three treatment groups in a randomized, double-

blind trial

that compared low-dose oral isotretinoin (10 mg/d), topically applied

tretinoin

(0.025% cream), and the combined use of both isotretinoin and

tretinoin. For the

first 16 weeks of the trial, subjects received one of these three

trial

regimens. For the final 16 weeks, isotretinoin was withheld while

tretinoin

cream or a placebo cream was continued. RESULTS: Twenty subjects

completed the

trial. Each treatment produced therapeutic benefits with regard to

the number of

papules and pustules and erythema. Treatment with oral isotretinoin

appeared to

give a more rapid onset of improvement, but there were no differences

between

the groups after 16 weeks. This level of improvement continued during

the

succeeding 16 weeks of observation whether the subjects used the

tretinoin or

the placebo cream. Adverse events were minimal and well tolerated in

all groups.

CONCLUSIONS: Low-dose oral isotretinoin and topical tretinoin cream

therapy

appear to be beneficial in the treatment of severe or recalcitrant

rosacea. No

additive benefit is noted with the combined use of these two

modalities.

Publication Types:

Clinical Trial

Randomized Controlled Trial

PMID: 8129410 [PubMed - indexed for MEDLINE]